Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
INKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.56 - $19.00
Previous CloseN/A
Volume98.55K
Average Volume (3M)52.36K
Market Cap
$39.06M
Enterprise Value$27.93M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 19, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding3,963,040
10 Day Avg. Volume14,286
30 Day Avg. Volume52,363
Standard Deviation0.24
R-Squared0.00116
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-136.52
Enterprise Value/Ebitda-2.01
Forecast
1Y Price Target
$7.00Price Target Upside-30.69% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
MiNK Therapeutics News
PremiumCompany Announcements
MiNK Therapeutics Reports Q3 Growth and Strategic Advances
PremiumCompany Announcements
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPatient enrollment in the Phase 2 IST testing AGENT-797 in patients with second-line gastric cancer has exceeded expectations, and initial data will be presented at a medical meeting.
Scientific AdvancementsMiNK's progress as it relates to studying AGENT-797 in acute GvHD, an area in which the scientific literature strongly supports development of an iNKT therapy, is encouraging.
Bears Say
Financial RisksReducing price target to $4/share to account for risks associated with potential future dilution.
---
Ownership Overview
28.89% Insiders
8.28% Mutual Funds
0.45% Other Institutional Investors
56.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $4.56 and its highest was $19.00 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $39.06M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Mar 19, 2025 which is in 24 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.801 by $0.301.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Overvalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.49.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 3,963,040 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.801. Following the earnings report the stock price went down -5.542%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
---
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (-30.69% Downside)
$7.00 (-30.69% Downside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.78%
12-Months-Change
Fundamentals
Return on Equity
78.50%
Trailing 12-Months
Asset Growth
-1.16%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
---
INKT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with significant advancements in clinical trials, efficient cost management, and promising data presentations at SITC. However, concerns about the cash position and early stages of the GVHD program indicate areas that require attention.Read More>---
INKT Stock 12 Month Forecast
Average Price Target
$7.00
▼(-30.69% Downside)
Technical Analysis
Best Analysts Covering INKT
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-10.24%
reiterated a buy rating 3 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -10.24% per trade.
---